Sysmex (OTCMKTS:SSMXY) Shares Gap Up – Here’s What Happened

Sysmex Corporation ADR (OTCMKTS:SSMXY) gapped up before the market opened on Monday . The stock had previously closed at $9.15, but opened at $9.79. Sysmex shares last traded at $9.80, with a volume of 2,851 shares.

Wall Street Analysts Forecast Growth

Separately, Zacks Research cut Sysmex from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Sysmex has a consensus rating of “Hold”.

Sysmex Stock Performance

The firm has a market cap of $6.14 billion, a price-to-earnings ratio of 25.66 and a beta of 1.07. The stock’s 50 day moving average is $9.08 and its 200 day moving average is $9.06. The company has a current ratio of 3.26, a quick ratio of 2.46 and a debt-to-equity ratio of 0.12.

Sysmex (OTCMKTS:SSMXY) last issued its quarterly earnings data on Thursday, May 14th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.02). Sysmex had a return on equity of 7.23% and a net margin of 7.13%.The company had revenue of $877.92 million for the quarter, compared to analyst estimates of $862.45 million. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. Analysts anticipate that Sysmex Corporation ADR will post 0.42 earnings per share for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.